A Theranos investor says the company never disclosed it wasn’t using its own tech

Brian Grossman of PFM Health Sciences tried to conduct detailed due diligence on Theranos, he testified in court.

PFM Health Sciences partner Brian Grossman

PFM Health Sciences partner Brian Grossman leaves the courthouse in San Jose Tuesday.

Photo: Biz Carson / Protocol

PFM Health Sciences partner Brian Grossman had a laundry list of due-diligence questions for the latest investment he was considering.

"How does your accuracy and speed stack up against your traditional tests?"

"What are the limitations of the technology? What tests are not feasible?"

The answers he got back from the company — Theranos — obfuscated the truth, he testified on Tuesday in the ongoing criminal fraud trial of Elizabeth Holmes, the blood-testing startup's co-founder and former CEO.

As he faced repeated questioning by Assistant U.S. Attorney Robert Leach, Grossman said he was never told that Theranos' own analyzers were only being used for a handful of tests. He did not know that modified commercial machines were being used, he said, and he "absolutely" did not know that Theranos' expenses included the cost of the Siemens machines it was using to test patient samples.

Instead, he said he was pitched on a 10-year-old company whose technology had been vetted, validated and used on the battlefield and medevac helicopters "in matters of life and death." In his first meeting with company executives in December 2013, he was told by Holmes and Sunny Balwani, Theranos' then-president who is also facing fraud charges, that it had taken Theranos a decade to get to the point where it could run every test on the menu of its largest competitors. They emphasized that their technology was "better than conventional lab equipment" with lower variability.

Grossman was particularly enamored with the potential Theranos had for replacing an entire laboratory in a box — a move that would have had major implications to the cost structure of health care if you could scale down the square footage and people needed to operate testing. And, importantly to Grossman, it was a technology that had made it beyond the lab and into Walgreens stores, being run on human samples.

"Was that impressive?" Leach asked. "Very," Grossman replied.

So far, much of the testimony from Theranos investors in the drawn-out trial has exposed gaps in due diligence and how FOMO overruled formal process. But Grossman's testimony has been notable for just how much due diligence his firm did and the pushback he had received from Theranos along the way.

"From a bigger-picture perspective, we wanted to understand if there was development technological risk, or if we were investing in a company that was past that proof of concept and the risks were commercial roll-out and business strategy," Grossman said.

When he tried to reach out to companies like Walgreens and United Healthcare, Balwani wouldn't allow him to talk to the companies, Grossman said.

"He said 'No, we are not comfortable with that. It would look badly if investors are asking to speak with the company,'" Grossman said. The PFM investor ended up talking to Channing Robertson, a Stanford professor and former board member, who signed off on the technology as not having serious risks.

Grossman then worked with Balwani to arrange a tour of the manufacturing facility and the lab at Theranos, but faced resistance because the company was concerned he would see unpatented work and it would "compromise their intellectual property." Balwani acquiesced and allowed him to visit after saying he'd move some machines, and when Grossman toured the manufacturing facility and the CLIA lab, he said he only saw miniLabs and not the third-party devices that often ran the tests.

Grossman also tried the Theranos miniLab himself, or at least attempted to.

He went to a Walgreens to have his own blood drawn, only to end up with a venous draw instead of a fingerstick prick. After the results came back past the promised four-hour window, Grossman raised concerns with Balwani, who assured him it was just a problem with a specific test.

An email shown in court revealed that Grossman's test had actually been run on a Siemens Immulite machine and not one of Theranos' proprietary devices, something he didn't know at the time. (A different analyst at PFM did successfully get a fingerprick test, the defense showed in their cross-examination.)

Defense attorney Lance Wade pressed Grossman on the idea that he should have known if his blood was being collected by a venous draw that the lab would've been using a third-party device, but Grossman said he believed the microsample, taken with a venous draw, meant it would still be used on the Theranos proprietary device designed for smaller samples.

"I would be concerned if someone was using a microsample from traditional methods and using that on traditional lab equipment," Grossman replied. "That would be concerning for me."

Wade noted that despite PFM's long list of diligence questions, it never explicitly asked if Theranos did use third-party devices. Grossman conceded his firm didn't pose that question.

Even with the hiccups in the diligence process, Grossman's fund went ahead and invested roughly $96 million because it believed the representations Holmes had made about Theranos' capabilities — without revealing what was really going on in the labs.

Grossman's testimony is expected to continue Wednesday.


Judge Zia Faruqui is trying to teach you crypto, one ‘SNL’ reference at a time

His decisions on major cryptocurrency cases have quoted "The Big Lebowski," "SNL," and "Dr. Strangelove." That’s because he wants you — yes, you — to read them.

The ways Zia Faruqui (right) has weighed on cases that have come before him can give lawyers clues as to what legal frameworks will pass muster.

Photo: Carolyn Van Houten/The Washington Post via Getty Images

“Cryptocurrency and related software analytics tools are ‘The wave of the future, Dude. One hundred percent electronic.’”

That’s not a quote from "The Big Lebowski" — at least, not directly. It’s a quote from a Washington, D.C., district court memorandum opinion on the role cryptocurrency analytics tools can play in government investigations. The author is Magistrate Judge Zia Faruqui.

Keep ReadingShow less
Veronica Irwin

Veronica Irwin (@vronirwin) is a San Francisco-based reporter at Protocol covering fintech. Previously she was at the San Francisco Examiner, covering tech from a hyper-local angle. Before that, her byline was featured in SF Weekly, The Nation, Techworker, Ms. Magazine and The Frisc.

The financial technology transformation is driving competition, creating consumer choice, and shaping the future of finance. Hear from seven fintech leaders who are reshaping the future of finance, and join the inaugural Financial Technology Association Fintech Summit to learn more.

Keep ReadingShow less
The Financial Technology Association (FTA) represents industry leaders shaping the future of finance. We champion the power of technology-centered financial services and advocate for the modernization of financial regulation to support inclusion and responsible innovation.

AWS CEO: The cloud isn’t just about technology

As AWS preps for its annual re:Invent conference, Adam Selipsky talks product strategy, support for hybrid environments, and the value of the cloud in uncertain economic times.

Photo: Noah Berger/Getty Images for Amazon Web Services

AWS is gearing up for re:Invent, its annual cloud computing conference where announcements this year are expected to focus on its end-to-end data strategy and delivering new industry-specific services.

It will be the second re:Invent with CEO Adam Selipsky as leader of the industry’s largest cloud provider after his return last year to AWS from data visualization company Tableau Software.

Keep ReadingShow less
Donna Goodison

Donna Goodison (@dgoodison) is Protocol's senior reporter focusing on enterprise infrastructure technology, from the 'Big 3' cloud computing providers to data centers. She previously covered the public cloud at CRN after 15 years as a business reporter for the Boston Herald. Based in Massachusetts, she also has worked as a Boston Globe freelancer, business reporter at the Boston Business Journal and real estate reporter at Banker & Tradesman after toiling at weekly newspapers.

Image: Protocol

We launched Protocol in February 2020 to cover the evolving power center of tech. It is with deep sadness that just under three years later, we are winding down the publication.

As of today, we will not publish any more stories. All of our newsletters, apart from our flagship, Source Code, will no longer be sent. Source Code will be published and sent for the next few weeks, but it will also close down in December.

Keep ReadingShow less
Bennett Richardson

Bennett Richardson ( @bennettrich) is the president of Protocol. Prior to joining Protocol in 2019, Bennett was executive director of global strategic partnerships at POLITICO, where he led strategic growth efforts including POLITICO's European expansion in Brussels and POLITICO's creative agency POLITICO Focus during his six years with the company. Prior to POLITICO, Bennett was co-founder and CMO of Hinge, the mobile dating company recently acquired by Match Group. Bennett began his career in digital and social brand marketing working with major brands across tech, energy, and health care at leading marketing and communications agencies including Edelman and GMMB. Bennett is originally from Portland, Maine, and received his bachelor's degree from Colgate University.


Why large enterprises struggle to find suitable platforms for MLops

As companies expand their use of AI beyond running just a few machine learning models, and as larger enterprises go from deploying hundreds of models to thousands and even millions of models, ML practitioners say that they have yet to find what they need from prepackaged MLops systems.

As companies expand their use of AI beyond running just a few machine learning models, ML practitioners say that they have yet to find what they need from prepackaged MLops systems.

Photo: artpartner-images via Getty Images

On any given day, Lily AI runs hundreds of machine learning models using computer vision and natural language processing that are customized for its retail and ecommerce clients to make website product recommendations, forecast demand, and plan merchandising. But this spring when the company was in the market for a machine learning operations platform to manage its expanding model roster, it wasn’t easy to find a suitable off-the-shelf system that could handle such a large number of models in deployment while also meeting other criteria.

Some MLops platforms are not well-suited for maintaining even more than 10 machine learning models when it comes to keeping track of data, navigating their user interfaces, or reporting capabilities, Matthew Nokleby, machine learning manager for Lily AI’s product intelligence team, told Protocol earlier this year. “The duct tape starts to show,” he said.

Keep ReadingShow less
Kate Kaye

Kate Kaye is an award-winning multimedia reporter digging deep and telling print, digital and audio stories. She covers AI and data for Protocol. Her reporting on AI and tech ethics issues has been published in OneZero, Fast Company, MIT Technology Review, CityLab, Ad Age and Digiday and heard on NPR. Kate is the creator of RedTailMedia.org and is the author of "Campaign '08: A Turning Point for Digital Media," a book about how the 2008 presidential campaigns used digital media and data.

Latest Stories